Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

INTRODUCTION: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). METHODS: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks fo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Alzheimers Dement (Amst)
Auteurs principaux: Carlson, Christopher, Siemers, Eric, Hake, Ann, Case, Michael, Hayduk, Roza, Suhy, Joyce, Oh, Joonmi, Barakos, Jerome
Format: Artigo
Langue:Inglês
Publié: Elsevier 2016
Sujets:
Neuroimaging
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879647/
https://ncbi.nlm.nih.gov/pubmed/27239538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dadm.2016.02.004
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires